Email updates

Keep up to date with the latest news and content from BMC Veterinary Research and BioMed Central.

Open Access Highly Accessed Research article

Tolerability and efficacy of the intestinal phosphate binder Lantharenol® in cats

Bernard H Schmidt1*, Ute Dribusch1, Peet C Delport2, Jürgen M Gropp3 and F Josef van der Staay4

Author Affiliations

1 Bayer Animal Health GmbH, Global Drug Discovery & Development, Building 6700, 51368 Leverkusen, Germany

2 ClinVet International Ltd, Bloemfontein, Republic of South Africa

3 Faculty of Veterinary Medicine, University of Leipzig, Germany

4 Emotion and Cognition Group, Farm Animal Health, University Utrecht, The Netherlands

For all author emails, please log on.

BMC Veterinary Research 2012, 8:14  doi:10.1186/1746-6148-8-14

Published: 6 February 2012



Tolerability and efficacy of the intestinal phosphate binder Lantharenol® (lanthanum carbonate octahydrate) were tested in two prospective, randomized and negative controlled laboratory studies with healthy adult cats fed commercial maintenance diets non-restricted in phosphorus. In the first study, the maximal tolerated dose was determined. Starting from a dose of 0.125 g/kg body weight mixed with the daily feed ration, the dose of Lantharenol® was doubled every other week until signs of intolerability were observed (N = 10 cats compared to 5 untreated controls). In the second study, the effects of feed supplementation for two weeks with approximately 2, 6, and 20% of the maximal tolerated dose on phosphorus excretion patterns and balance were assessed (N = 8 cats per group).


Lantharenol® was found to be safe and well tolerated up to the dose of 1 g/kg bodyweight, corresponding to a concentration of 84 g Lantharenol®/kg complete feed, defined as dry matter with a standard moisture content of 12%. Feed supplementation for two weeks with approximately 2-20% of this dosage (i.e., 1.6, 4.8, and 16 g/kg complete feed) resulted in a shift from urinary to faecal phosphorus excretion. Apparent phosphorus digestibility was dose-dependently reduced compared to the control group fed with diet only (N = 8).


The feed additive was well accepted and tolerated by all cats. Therefore, Lantharenol® presents a well tolerated and efficacious option to individually tailor restriction of dietary phosphorus as indicated, for instance, in feline chronic kidney disease.